HUTCHMED (China) (HCM) Net Income towards Common Stockholders (2015 - 2021)

HUTCHMED (China)'s (HCM) quarterly Net Income towards Common Stockholders came in at $143.5 million in Q2 2021, up 1038.03% year-on-year from $12.6 million in Q2 2020, and up 448.88% on a QoQ basis from -$41.1 million in Q1 2021.

HUTCHMED (China) (HCM) Net Income towards Common Stockholders (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HCM) has 6 years of Net Income towards Common Stockholders data on file, last reported at $143.5 million in Q2 2021.

  • On a quarterly basis, Net Income towards Common Stockholders rose 1038.03% year-over-year to $143.5 million in Q2 2021; TTM through Dec 2022 was $143.5 million, a 40.18% increase from a year earlier, with the FY2025 full-year figure at $22.4 billion, changed 0.33% from the prior year.
  • Net Income towards Common Stockholders for Q2 2021 stood at $143.5 million, up from -$41.1 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for HCM reached as high as $143.5 million in Q2 2021 and fell as low as -$121.8 million in Q3 2019.
  • Historically, Net Income towards Common Stockholders has averaged $5.6 million across 4 years, with a median of $14.6 million in 2018.
  • Across the five-year window, Net Income towards Common Stockholders tumbled 576.31% in 2019 and jumped 1038.03% in 2021, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at $16.5 million in 2018, then tumbled by 278.77% to -$29.6 million in 2019, then jumped by 142.67% to $12.6 million in 2020, then soared by 1038.03% to $143.5 million in 2021.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $143.5 million in Q2 2021, -$41.1 million in Q1 2021, and $12.6 million in Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 57.00 Mn
10 HUTCHMED (China) 9.45 Bn 9.45 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2021 143.54 Mn
Mar 31, 2021 -41.14 Mn
Jun 30, 2020 12.61 Mn
Mar 31, 2020 -16.14 Mn
Dec 31, 2019 -29.56 Mn
Sep 30, 2019 -121.83 Mn
Jun 30, 2019 25.48 Mn
Mar 31, 2019 19.89 Mn
Dec 31, 2018 16.54 Mn
Sep 30, 2018 25.58 Mn
Jun 30, 2018 44.42 Mn
Mar 31, 2018 -11.73 Mn
Jun 30, 2016 29.56 Mn
Jun 30, 2015 23.49 Mn